InMed Pharmaceuticals (INM) Revenue (2021 - 2025)

InMed Pharmaceuticals has reported Revenue for 5 years, with the latest figure at $820188.0 in Q4 2025.

• On a quarterly basis, Revenue fell 26.22% year-over-year to $820188.0 in Q4 2025; TTM through Dec 2025 was $4.5 million, a 6.73% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, up 7.5% from the prior year.
• Revenue was $820188.0 for Q4 2025 at InMed Pharmaceuticals, down from $1.1 million in the prior quarter.
• The five-year high for Revenue was $2.3 million in Q2 2023, with the low at $265092.0 in Q4 2021.
• Average Revenue over 5 years is $999769.6, with a median of $1.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Revenue jumped 348.96% in 2023, then slumped 44.48% in 2024.
• Over 5 years, Revenue stood at $265092.0 in 2021, then soared by 77.22% to $469783.0 in 2022, then surged by 163.99% to $1.2 million in 2023, then decreased by 10.36% to $1.1 million in 2024, then fell by 26.22% to $820188.0 in 2025.
• The last three Revenue figures came in at $820188.0 (Q4 2025), $1.1 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.